tbuckley/cabot-search huggingface dataset:
Abstract 5321: Longitudinal high throughput CT imaging of orthotopic lung tumors in mice without using contrast media or respiratory gating
Authors: Christopher M. Bull, Li Li, Michael S. Westmore, Jeffrey A. Wolos
Journal: Cancer Research (2011)

Abstract In the clinic, CT is the primary clinical imaging modality for diagnosing and staging tumors of the lungs because of its high speed, ability to differentiate between lung and tumor tissue, and relatively low cost. The high contrast between tumor and lung tissue provides accurate identification of tumors without the need for contrast agents. The injection of cells from the pulmonary adenocarcinoma cell line NCI-441 directly into the lung results in localized tumor growth. Using this orthotopic model, we have developed a technique for imaging tumor growth in 12 mice simultaneously using the GE eXplore Locus Ultra CT scanner. Image acquisition requires only 8 seconds and delivers quantifiable data without the need for respiratory gating. Athymic nude mice were injected with NCI-H441 cells into the left lung. Lungs were imaged by CT every 7 days starting on day 7 post-inoculation. The images were analyzed using GE MicroView software by drawing contours on selected slices through the tumors and using the interpolation technique to generate a volumetric region defining the tumor. Twenty one days after inoculation the animals were imaged and mice with similar sized tumors were randomized into three groups (vehicle, gemcitabine 75 mg/kg, gemcitabine 150 mg/mg) and treated IP once every 3 days, through 4 cycles. CT analysis enabled the elimination of non-tumor bearing mice and mice with extremely large tumors. Substantial tumor growth was observed in the vehicle group, with nearly complete inhibition in the two gemcitabine groups. These results demonstrate the development of a robust, simple, and high-throughput model for quantifying orthotopic lung tumors in mice. Using CT for recruitment and longitudinal evaluation of tumor growth will reduce the numbers of animals needed per group while allowing rapid differentiation between compounds or doses. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5321. doi:10.1158/1538-7445.AM2011-5321
Communicating in Organizations, Part I
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2012)

Communication skills are important for all members in an organization, and especially the leaders. Leaders must be proficient in many different types of conversations, such as one-on-one dialogue, group meetings, speeches, electronic exchanges of messages, newsletters, question and answer sessions with various stakeholders and the media, and so forth. This series of articles will review some important aspects of communication within an organization.
GE-22 * IMMUNOHISTOCHEMICAL MOLECULAR EXPRESSION PROFILING FOR GLIOBLASTOMA
Authors: H. Nishihara, M. Miyazaki, H. Kobayashi, S. Terasaka, S. Tanaka
Journal: Neuro-Oncology (2014)

Molecular diagnosis based on gene expression profiling has been indispensable and essential examination for individualized cancer treatment especially for brain tumor including glioblastoma. Gene chip analysis and exome sequencing are recently utilized for this purpose, although these approaches are still far from hospital-level routine laboratory examination because of their demand of highly advanced techniques and excessive cost. Here we established an immunohistochemical molecular profiling analysis to obtain the protein expression profile of multiple receptor tyrosine kinases (RTKs). We performed immunostaining of 63 cases of glioblastoma and quantitated the expression levels of EGFR (epidermal growth factor receptor), PDGFR-alpha (platelet-derived growth factor receptor alpha) and cMET in tumor cells. Based on the analogical heat map analysis of immunohistochemistry, all 63 cases were categorized into 4 subgroups of MET-high, EGFR-high, PDGFRA-high and RTK-int/low. Interestingly, survival analysis revealed that MET-high and RTK-high groups showed significantly unfavorable prognosis compared to the other groups. This is the first report to demonstrate the immunohistochemical molecular profiling combined with heat map technique, and we indicates that our method is worthy for the personalized diagnosis as a routine laboratory examination especially for glioblastoma patients.
Unusual Cases of Pulmonary Arteriovenous Fistulas, with a Note on Thyroid Carcinoma as a Cause
Authors: John A. Pierce, W. Paul Reagan, Robert W. Kimball
Journal: New England Journal of Medicine (1959)

MULTIPLE small pulmonary arteriovenous fistulas are recognized as a cause of central cyanosis, clubbed fingers and polycythemia. It has been held that these fistulas result from congenital vascular anomalies. Recent evidence suggests that some such lesions may not be congenital in origin. It is the purpose of this report to review that evidence and to present data on 2 patients with multiple small pulmonary arteriovenous fistulas, 1 of whom exhibited a previously unrecognized form of this disease. The other patient had congenital fistulas, but presented the unusual complication of cirrhosis of the liver.Method of StudyPertinent to the study . . .
AB0512 Biological treatment of still’s disease. Report of seven pacients
Authors: B. Tejera, A. Riveros, D. Grados, M. Martinez-Morillo, S. Rodriguez, S. Holgado, L. Mateo, A. Olivé, X. Tena
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Still's disease is a rare systemic entity of unknown etiology,characterized by fever peaks with evanescent rash, arthritis and/or joint pain that is associated with odynophagia, lymphadenopathy and hepatosplenomegaly. Diagnosis is difficult and exclusion. Treatment has varied over time. Systemic glucocorticoidsare the first choice, although biological drugs are an alternative for refractory cases. <h3>Objectives</h3> Describe the clinical characteristics and evolution of a series of patients diagnosed with Still's disease who have followed biological treatment. <h3>Methods</h3> Retrospective (1978-2011). UniversityHospital with a referal area of 800,000 inhabitants. We reviewed the medical records of patients from the database section of Rheumatology.Inclusion criteria: patients with Still' disease following Yamaguchi critera who were treated with biological drugs. <h3>Results</h3> Seven patientswere selected: 5 women (71.5%) and 2 men (28.5%).The mean age at diagnosis was 30.2 (16-58).All hadsore throat,fever and allbut onerash.All hadpolyarthralgia. Six patients (85.7%) polyarthritis and one oligoarthritis.Four patients (57.1%) had splenomegaly, lymphadenopathy 2 of them (28.5%). Two patients did not have any of these clinical signs.Serositiswas foundonlyin one patient. Inlaboratory data yielded: leukocytosis with neutrophilia in 2 patients (28.5%), anemia (hb ≤12 g/dL in 3 patients (42.9%). Ferritinwas elevatedin two patients. The ESR was elevated in 4 cases (57.4%), with a mean of 45±39.53 mm in the first hour. The CRP was elevated in six patients (85.5%) with an average of 27.5 mg/L. Mean follow-up: 70 months. The form of evolution of the disease was polycyclic in 4 patients and monocyclic in three. Biological treatment was: anakinra in 5 patients (71.5%), etanercept, 2 patients (28.5%), tocilizumab, two patients (28.5%).In addition, one patient was refractory to all biologicals(infliximab, rituximab, anakinra,tocilizumab, abatacept). Three patients (60%) treated with anakinra achieved complete remission. The other two patients without remission, were treated with tocilizumab with a good response in one case. The remaining patientwas treated well with infliximab, rituximab, anakinra and tocilizumab. All treatments weerretired because of serious side effects or ineffectiveness. This patient is currently treated with abatacept with good response although is not achieving complete remission. The 2 patients treated with etanercept achieved complete remission. <h3>Conclusions</h3> Biological therapy as treatment for refractory Still's disease was effective in most cases. Anakinra was the drug most widely used and more than half of patients who were treated with it, achieved complete remission. <h3>Disclosure of Interest</h3> None Declared
Klippel-Trénaunay Syndrome (KTS) Evaluated With Bone and Labeled RBC Scintigraphy
Authors: Elbio Schächner, Joseph E. Glaser, Leonard M. Freeman
Journal: Clinical Nuclear Medicine (2013)

This is a case of a 4-year-old female child with gross left lower extremity deformity detected at birth, including a giant cutaneous hemangioma from flank to foot. She was found to have no other associated abnormalities and was diagnosed with Klippel-Trénaunay syndrome. This is a rare entity and literature regarding use of radionuclide imaging techniques to evaluate this is scarce. We present here bone and red cell scans performed to evaluate whether there was osseous involvement or only soft tissue disease, which showed classic signs of this condition. Patient photographs also show the syndrome’s typical appearance.
Endoscopic ultrasonography at the choice of optimum medical tactics at esophagogastric varices
Authors: NV Tashkinov, SI Chichkan, AV Pirch, YS Sigaeva
Journal: Endoscopy (2011)

Objective of the study: Bleeding from esophagogastric varices is a catastrophic complication of chronic liver disease. Endoscopic ultrasonography can clearly depict vascular structures around the esophageal wall in patients with portal hypertension. The aim of this study was to determine role ultrasonography at a choice of optimum medical tactics at esophagogastric varices.
PMO-005 Brief intervention reduces future hospital attendance in hazardous alcohol drinkers
Authors: A Assad-Sangabi, R Smith, J Cleminson, L Jones, D Elphick
Journal: Gut (2012)

<h3>Introduction</h3> Excessive alcohol consumption is a major health burden facing the NHS. The Fast Alcohol Screening Tool (FAST) is a useful, simple tool to screen for hazardous/harmful drinking. Hazardous drinking is associated with a high risk of psychological or physical problems in the future. In this study, we assess the FAST score in patients attending the Emergency Department (ED) of our hospital. We then evaluate whether brief alcohol intervention on high scorers (hazardous drinkers), in the form of consultation and advice on alcohol related habits, results in fewer future ED attendances. <h3>Methods</h3> All those, 18 years and over, attending the ED of Chesterfield Royal Hospital over a 24 h period were asked to take part in this study. All participants were formally consented. Patient demographics were taken, and reason for admission noted. Number of prior ED attendances were noted from hospital records and patient recollection. FAST questionnaires were then filled, followed by a brief intervention [typically lasting 10 min] given to those who scored 3 or above. Investigators had prior training on brief intervention. Frequency of hospital attendance following this episode was then taken from hospital records. <h3>Results</h3> 140 patients attended ED, but 25 were excluded (declined participation, life-threatening illness). Therefore, 115 patients participated in the study (60 (52%) female and 55 (48%) male; median age 47). FAST score was 0 in 60 (52%), 1 in 13 (11%), 2 in 19 (17%) and ≥3 in 23 (20%) patients. Brief alcohol intervention was carried out in 19 out of 23 patients who scored ≥3 (not possible in four who were intoxicated with alcohol). These included 9 (48%) female and 10 (52%) male with median age of 39. In this subgroup of patients, 15 had no previous ED attendances, one attended once, one attended twice and two attended three times each in the prior 6 months. Therefore, four out of 19 (21%) of these patients attended ED on a total of nine occasions over that 6 months. 20 out of 92 patients (22%) of those with FAST score &lt;3 had prior admissions over the same period with a total of 25 attendances. Two out of 19 (10%) patients with FAST score ≥3, who were given brief intervention, re-attended over the following 6 months, on one occasion each (total two attendances). 13 out of 92(14%) patients with FAST score &lt;3 re-attended over this time period, with total 17 attendances. Brief intervention therefore appeared to reduce future hospital attendance in hazardous alcohol drinkers. <h3>Conclusion</h3> Hazardous alcohol drinkers (with FAST scores ≥3) make up a large proportion of those attending ED. Brief alcohol intervention for these reduces their re-attendance. We therefore recommend front-line ED staff to be trained in brief intervention. <h3>Competing interests</h3> None declared.
AB0073 Measurement of the Anti-Inflammatory Molecule Glucocorticoid-Induced Leucine Zipper (GILZ) in Rheumatoid Arthritis Patients
Authors: L.E. Eades, A.S. Thiagarajah, A.C. Gist, S.A. Jones, J. Harris, Y.H. Yang, H. Fan, A. Foote, E.F. Morand, M. Leech
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Rheumatoid arthritis (RA) affects 1% of populations worldwide. Approximately 30% of RA patients receive treatment with glucocorticoids (GC), which cause significant toxicity (1). Glucocorticoid-induced leucine zipper (GILZ) is a GC-induced protein, which mediates many of the anti-inflammatory effects of GC, suggesting manipulation of GILZ as a potential therapeutic approach in RA (2,3). However, little is known regarding GILZ expression in RA. <h3>Objectives</h3> We aimed to detect GILZ in peripheral blood mononuclear cells (PBMC) of RA patients, examine the relationship between GILZ expression, disease activity and GC use, and assess GILZ expression relative to the expression of pro-inflammatory cytokines. <h3>Methods</h3> Blood was collected from 86 RA patients and three control cohorts (23 healthy controls, 30 patients with fibromyalgia and 48 patients with depression). Clinical information regarding medications and disease activity was also obtained from RA patients. qRT-PCR was performed to quantify expression of GILZ, IL-6 and TNFα mRNA in PBMC. Enzyme-linked immunosorbent assay (ELISA) was performed to quantify serum IL-6 concentration. <h3>Results</h3> GILZ expression was increased in RA patients compared with healthy controls (<i>p</i>=0.002), patients with depression (<i>p</i>=0.007) and patients with fibromyalgia (<i>p</i>=0.046). GILZ expression correlated positively with disease activity (DAS28-ESR) in active RA (<i>p</i>=0.025) and was significantly increased in patients taking prednisolone (<i>p</i>=0.009). Compared to controls, GILZ:IL-6 (<i>p</i>=0.026) and GILZ:TNFα (<i>p</i>=0.005) ratios were significantly increased in RA. <h3>Conclusions</h3> GILZ expression is increased in RA, and correlates with disease activity and GC use. Increased GILZ:cytokine ratios in RA suggest that GILZ expression may be increased in order to suppress inflammatory cytokines in vivo. These data support further research into the potentiation of GILZ as a possible steroid-sparing therapeutic approach in RA. <h3>References</h3> O9Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2591-602. Ayroldi E, Migliorati G, Bruscoli S, Marchetti C, Zollo O, Cannarile L, et al. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB. Blood. 2001 Aug 1;98(3):743-53. Beaulieu E, Morand EF. Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis. Nature reviews Rheumatology. 2011 Jun;7(6):340-8. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3176
Abstract LB-357: HIF-dependent over-expression of CUB domain-containing protein 1 stimulates migration in clear cell renal cell carcinoma
Authors: Olga V. Razorenova, Elizabeth C. Finger, Renata Colavitti, Sophia B. Chernikova, Alexander D. Boiko, Charles KF Chan, Adam Krieg, Barbara Bedogni, Edward LaGory, Irving L. Weissman, Marianne Broome-Powell, Amato J. Giaccia
Journal: Cancer Research (2011)

Abstract Kidney cancer is the sixth leading cause of cancer death in the USA, and the primary tumor is frequently accompanied by metastasis to lungs, liver, brain and bones. Importantly a large number of kidney cancer cases are characterized by loss of von Hippel-Lindau (VHL) gene, which leads to stabilization of hypoxia-inducible factors (HIFs), which contribute to tumor progression and metastasis by multiple mechanisms. CUB-domain-containing protein 1 (CDCP1) was shown to be expressed on the cell surface of metastatic cell lines and to increase the number of nodules formed by lung adenocarcinoma cells and melanoma in lungs in tail vein injection experiments, enhance peritoneal dissemination of scirrhous adenocarcinoma, and to induce metastasis in the chicken embryo metastatic model. In the present study we investigated the role of CDCP1 protein in clear cell renal cell carcinoma (CC-RCC) and found it to be upregulated in this disease entity by a mechanism of VHL loss through HIFs. Interestingly, we found CDCP1 protein expressed not only on the membrane of kidney cancer cell lines, but also to be secreted into the media as a full length isoform. Importantly, in the knockdown experiments we found CDCP1 to promote CC-RCC cell migration in vitro, the process known to be the key during metastasis. Accordingly CDCP1 participates in the signal transduction pathway leading to PKCδ phosphorylation in CC-RCC, stimulating migration. The role of PKCδ in CDCP1-dependent migration was verified by the PKCδ knockdown experiments, which phenocopy the effect of CDCP1 knockdown; as well as migration rescue experiments, where the impairment of migration caused by CDCP1 downregulation was rescued by the overexpression of constitutively active mutant of PKCδ. Furthermore, we showed a correlation of CDCP1 cell surface expression in primary tumor with poor patient outcome. Finally, we found that suramin, a drug, which showed the clinical benefit for CC-RCC patients at premetastatic stages, causes the downregulation of CDCP1 at the protein level. Thus, the further investigation of the role of CDCP1 protein in kidney cancer metastasis is important to validate CDCP1 as a therapeutic target. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-357. doi:10.1158/1538-7445.AM2011-LB-357
Metastasis of Renal-Cell Carcinoma
Authors: Fabrizio Pugliese, Valentino Pagliuca
Journal: New England Journal of Medicine (2011)

Four years after a right nephrectomy for renal-cell carcinoma, an 89-year-old man was referred for evaluation of a pulsating mass on the fourth digit of the right hand. The mass had increased in size during the preceding 3 months after minor trauma to the finger.
The question should be whether the timing of vaccination optimises the impact on child health
Authors: Ane B Fisker
Journal: BMJ (2016)

Rather than asking whether there is evidence that the timing of the vaccination programme prevents the targeted diseases, the question should be whether the timing optimises the impact on child health.1

That evidence base is insufficient. In low income countries, where the burden of child mortality lies, the vaccines at the core of the Expanded Programme on Immunization were not evaluated for their …
Efficacy and Safety of Intracavernosal Alprostadil in Men with Erectile Dysfunction
Authors: Otto I. Linet, Francis G. Ogrinc
Journal: New England Journal of Medicine (1996)

Erectile dysfunction is a common medical problem affecting many men. Although several intracavernosal therapies are available, their efficacy and safety have not been studied systematically.We investigated the efficacy and safety of alprostadil formulated for intracavernosal treatment in three separate multi-institutional, prospective studies in men with erectile dysfunction of vasculogenic, neurogenic, psychogenic, and mixed causes. Clinical and laboratory evaluations of erection and the feasibility of satisfactoriness of sexual activity as assessed both by the men and by their partners were the primary measures of efficacy.In a dose-response study of 296 men, all doses of alprostadil were superior to placebo and there was a significant dose-response relation (P < / = 0.001), resulting in higher response rates with increasing doses of alprostadil (from 2.5 to 20 microg). In a dose-finding study of 201 men, the minimal effective dose was < / = 2 microg in 23, 20, 38 and 23 percent of men with erectile dysfunction of neurogenic, vasculogenic, psychogenic, or mixed causes, respectively. In a six-month self-injection study in 683 men, the participants reported being able to have sexual activity after 94 percent of the injections. The men and their partners rated the sexual activity as satisfactory after 87 and 86 percent of the injections, respectively. Penile pain, usually mild, occurred in 50 percent of the men at some time but after only 11 percent of the injections. Prolonged erections occurred in 5 percent of the men, priapism in 1 percent, penile fibrotic complications in 2 percent, and hematoma or ecchymosis in 8 percent.In men with erectile dysfunction, intracavernosal injection of alprostadil is an effective therapy with tolerable side effects.
ABSOLUTE UPTAKE, CORTICAL DISTRIBUTION AND WASHOUT OF I-123 IODOAMPHETAMINE (IMP) IN A GROUP OF NORMAL PATIENTS.
Authors: G. Lamoureux, R. M. Dupont, J. C. Gillin, W. L. Ashburn, S. E. Halpern, U. de Sherbrooke, Sherbrooke P. Quebec
Journal: Clinical Nuclear Medicine (1988)

Lamoureux, G.; Dupont, R. M.; Gillin, J. C.; Ashburn, W. L.; Halpern, S. E.; de Sherbrooke, U.; Quebec, Sherbrooke P. Author Information